Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Oramed Pharmaceuticals Inc.

ORMP

Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.

Last trade $3.93
Day change +$0.03 (+0.77%)
Day range $3.84 – $3.96
Volume 104,095
Market cap $170M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$169.6M
Price / earnings
1.18×
Price / book
0.5×
Price / sales
—
EV / sales
—
EV / EBITDA
-8.75×

Profitability

Earnings per share
$3.31
Return on assets
35.94%
Return on equity
42.49%
Dividend yield
6.19%

Liquidity and leverage

Debt / equity
0×
Current ratio
6.07×
Quick ratio
6.07×
Cash ratio
3.06×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$68.13M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ORMP, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$2M$0
Cost of revenue$0$0$0$0$0$0$1.99M$0
Gross profit$0$0$0$0$0$0$13K$0
Selling, general and administrative$4.1M$2.77M$2.07M$3.68M$1.27M$1.46M$2.31M$2.13M
Research and development$0$0$1.59M$1.99M$1.15M$1.03M$2.21M$1.46M
Total operating expenses$4.1M$2.77M$3.66M$5.67M$2.43M$2.49M$4.51M$3.6M
Operating income-$4.1M-$2.77M-$3.66M-$5.67M-$2.43M-$2.49M-$4.5M-$3.6M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes$28.28M$101.59M$49.44M$9.8M$59.45M$13.13M-$7.06M-$9.78M
Income taxes$9.87M$23.43M$11.13M-$212K$11.06M-$126K$584K$416K
Net income$18.41M$78.16M$38.31M$10.01M$48.39M$13.26M-$7.64M-$10.2M
Net income attributable to common shareholders$18.41M$78.16M$38.31M$9.2M$48.4M$13.29M-$7.64M-$10.19M
EBITDA-$4.07M-$2.74M-$3.63M-$5.64M-$2.4M-$2.46M-$4.47M-$3.56M
Basic earnings per share$0.44$1.90$0.94$0.23$1.16$0.32-$0.19-$0.25
Diluted earnings per share$0.43$1.84$0.91$0.21$1.13$0.31-$0.19-$0.26

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) announced it will be added to the Russell 2000® and Russell 3000® indexes following the 2026 semi-annual reconstitution, effective June 29, 2026. The inclusion is based on the company's market capitalization ranking as of April 30, 2026, and will provide automatic inclusion in appropriate growth and value style indexes.

GlobeNewswire Inc.

Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company

Lifeward Ltd. announced shareholder approval for a strategic partnership with Oramed Pharmaceuticals, integrating Oramed's POD™ oral delivery technology platform. The deal provides Lifeward with up to $47 million in capital while allowing the company to diversify from its core medical technology business into biotechnology. Oramed will manage and fund the POD™ platform's clinical development, while Lifeward maintains focus on profitability from its existing ReWalk® and AlterG® product lines.

Benzinga

Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments

Oramed Pharmaceuticals received an $18 million payment from Scilex Holdings, closing out option agreement obligations and bringing total returns to $118 million on its original $99.5 million investment. The company's board approved a $0.25 per share cash dividend (~$10.5 million aggregate) to be paid on January 26, 2026. Oramed retains $39 million in outstanding debt, convertible notes, warrants, and royalty interests with Scilex.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Jan 16, 2026$0.25Jan 26, 2026unknown

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jan 23, 20131-for-12reverse split